Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Medipost Logo
Medipost Growth Score
77
CB Rank
48500
Heat Score
73
Medipost mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.
Founded
obfuscation
PublicPost-IPO Equity Seongnam, Kyonggi-do, South Korea51-100 www.medi-post.com/
Biotechnology
Overview

Medipost
Total Funding
obfuscation
Growth Score
77
Heat Score
73

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score77
1 pts
in past quarter
Heat Score 73
4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Medipost

CB Rank
48500
Medipost mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.
Founded
obfuscation
PublicPost-IPO Equity Seongnam, Kyonggi-do, South Korea51-100 www.medi-post.com/
Biotechnology

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Private Equity
OBF
in
obfuscation

Key People

Details

Legal Name Medipost
Operating Status Active
Stock Symbol  KOSDAQ:078160
Company Type For Profit
About the Company

MEDIPOST’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST is

the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012.

Phone Number +82 2-3465-6677
Predictions & Insights

Growth Insight

See this Growth Insight
Medipost is
Lorem
 to be growing
Top Contributing Factors
Market Share Expansion

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

CARTISTEM®
An allogeneic umbilical cord blood-derived mesenchymal stem cell product for surgical treatment of knee cartilage defects caused by osteoarthritis or trauma.
PNEUMOSTEM®
A mesenchymal stem cell therapy derived from human umbilical cord blood for intratracheal administration to treat bronchopulmonary dysplasia in preterm infants.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Medipost Logo
Post-IPO Equity - Medipost
2
obfuscation
Crescendo Equity Partners, Skylake Equity PartnersPost-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 1 Contacts 4

Employee Profiles

News

News and Press

News•Jun 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Actively Used Products

7Medipost uses 7 technology products and services including HTML5, Microsoft Outlook, and  Google Fonts, according to G2 Stack.

Total IP

40The intellectual property of Medipost includes 37 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Medipost has registered 3 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Medipost's headquarters? Medipost is located in Seongnam, Kyonggi-do, South Korea.Who invested in Medipost? Medipost has 5 investors including Crescendo Equity Partners and  Skylake Equity Partners.When was the last funding round for Medipost? Medipost closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Medipost's competitors? Alternatives and possible competitors to Medipost may include StemInov, Elpis Cell Therapeutics, and  Medinno.How much funding has Medipost raised to date? Medipost has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3ff49e4 1)
|